Navigation Links
Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
Date:8/6/2009

UMEA, Sweden, August 6 /PRNewswire/ -- Omnio Healer AB, a pioneer company developing novel therapies for wound healing and anti-infection, today announced that it has entered into a partnership agreement with Eden Biodesign. Under the agreement Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer's lead recombinant protein candidate.

Based on a novel therapeutic concept for wound healing and anti-infection, Omnio Healer is developing drug candidates with potent pro-inflammatory functions. The agreement with Eden Biodesign relates to the expression of proteins using mammalian cell culture for use against several clinical indications, but primarily for studies relating to chronic eardrum wounds.

Omnio Healer selected Eden Biodesign as its preferred manufacturing partner after an extensive due diligence exercise that evaluated numerous contract manufacturing organizations in both Europe and the United States. Eden Biodesign will undertake the development of a robust manufacturing process for the product leading to cGMP production for supplying clinical studies. Omnio Healer has also assessed Eden Biodesign as a potential future commercial manufacturer of the product using Eden's MHRA-inspected state-of-the-art cGMP manufacturing facilities located in Liverpool, UK.

Mats Stromqvist, CEO of Omnio Healer AB, said, "Our protein product has shown very promising preclinical results in wound healing indications. We are now very keen to take the next step and gain access to GMP-material for use in clinical trials. At the same time, we have every confidence that Eden Biodesign will become a valuable partner in this regard, providing both cGMP process development and production."

Eden Biodesign's CEO, Dr. Crawford Brown, commented, "We are extremely happy to have been selected by Omnio Healer to support the development of this important product. Based on our extensive experience, industry expertise and first class facilities we hope to be able to add considerable value and flexibility to Omnio Healer's development program."

About Omnio Healer

Omnio Healer AB is a pioneer company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved very promising preclinical results and will enter a clinical development program in late 2010.

Since its foundation in 2006 Omnio Healer has assembled a strong management and development team. This includes world-renowned scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a highly qualified network of biotechnology development resources. The company is based in Umea, Sweden. Find out more at http://www.omniohealer.com.

About Eden Biodesign

Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design and cGMP manufacturing services to leading biotech and pharmaceutical clients around the world. With a reputation for successfully commercializing biopharmaceutical products and processes, the company offers expertise and guidance in multiple sectors. Eden's world-class facilities and knowledge in process development, manufacturing, regulatory and technology transfer support ensure that Eden Biodesign offers much more than a traditional CMO. Find out more at http://www.EdenBiodesign.com.

    For more information, contact:

    Omnio Healer AB
    Mats Stromqvist, PhD, Professor, CEO Omnio Healer AB
    Tel. +46-70-631-0035
    info@omniohealer.com

    Eden Biodesign
    John D. Wagner, Propel Marketing Group
    Tel. +44-919-796-9984
    Jdwagner@PropelMG.com
   http://www.PropelMG.com



'/>"/>
SOURCE Omnio Healer AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing
2. CURE Magazine Announces Winner of 2008 Extraordinary Healer Award
3. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
4. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
5. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
6. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
7. GeneSeek Selects the British Midlands as Base for New UK/European Operations
8. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
9. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
10. ProCure Selects IMPAC as Provider of Oncology Information Systems
11. CIGNA Medical Group Selects Allscripts for Electronic Health Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... PLAINVIEW, N.Y. , Jan. 18, 2017 ... pathology services, announces the formation of an Executive Committee ... 2017 and beyond. John Cucci , ... been promoted from Director of Business Development to ... in 2015, Mr. Cucci served in senior sales leadership ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on ... Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion on ...
(Date:1/18/2017)... ... January 18, 2017 , ... Researchers from a new study are stating that ... enough after prostate cancer treatment, this indicates there is still remaining prostate cancer cells that ... “ The PSA test has always been an indicator of whether a man’s prostate cancer ...
Breaking Biology Technology:
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):